CHIKUNGUNYA VACCINE PROJECT,
Abstract
The comparative immunogenicities of experimental, formalin-killed chikungunya vaccines prepared in CE, SMB and GMK tissue culture are described. Mouse protection tests revealed that CE vaccine was markedly inferior to either SMB or GMK vaccine. Both SMB and GMK vaccine were highly effective in protecting mice against an IC challenge. However, the potentially encephalitogenic properties of SMB vaccines seriously limit their practical application. Plaque-inhibition and serum N tests revealed that GMK vaccine elicited significant levels of N antibody in mice to the mayaro virus and heterologous strains of the CHIK virus. To interpret these findings in terms of actual protection, a vaccine trial was performed in rhesus monkeys. After 3 doses of GMK vaccine, monkeys developed high levels of N antibody and, in most instances, detectable amounts of CF and HI antibody. The broad-spectrum protective capability of GMK vaccine was clearly defined by the absence of viremia, with one exception in the vaccinated monkeys, while all of the control monkeys developed viremias after challenge with either the mayaro virus or heterologous African and Asian strains of the CHIK virus. (Author)
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 1968
- Accession Number
- AD0837125
Entities
People
- Venton R. Harrison
Organizations
- Walter Reed Army Institute of Research